Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. Investor Contact Stern Investor Relations, Inc. Christina Tartaglia christina@sternir.com (212) 362-1200. Leveraging decades of industry learnings, we have developed proprietary and highly differentiated ADC platforms and expertise to rapidly design and test novel ADCs and identify those with optimal efficacy, safety … Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants. Mersana Therapeutics serves the … This book comprehensively covers a broad range of therapeutic and diagnostic applications of nanotechnology, providing descriptions of cutting-edge discoveries along with historical perspectives. Secure and cloud-based. Found inside – Page 217Expert Opinion on Therapeutic Patents, 19, 555–574. Feun, L. and Savaraj, ... Molecular Cancer Therapeutics, 8 (12), B52. www.mersana. Tushar was most recently EVP, Head of Technical Development & Manufacturing at Laronde, a platform company … The current price level -55.28% lower than the highest price of $29.09 marked by the stock while trading over the past 52-weeks, whereas it is 25.82% higher than the lowest price of $10.34 the company dropped to over past 52-weeks. The stock has traded between $13.83 and $14.42 so far today. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. This number is assigned once our patented identity resolution process, part of our DUNSRight, Learn about how a Dun & Bradstreet D-U-N-S number can help your company succeed, Establish your business, get noticed, and control your story in the global marketplace, Look up a partner’s company or find your company’s D-U-N-S Number, View and update business information on your D&B Credit file, A leading global provider of business decisioning data and analytics for almost 200 years, Live Business Identity is the most comprehensive and continually updated view of a business entity, Our always-open marketplace for unique offers that help your business grow and thrive, Drive performance through our partnership program, D&B Accelerate, Information and resources about the performance of Dun & Bradstreet. There are 2 companies in the Mersana Therapeutics, Inc. corporate family. Combine your data with Dun & Bradstreet Data Cloud data to create new analytical models that can give you a competitive edge. Install plugin and receive up to 50 free email contacts per month! Corporate Governance Mersana Therapeutics, Inc.’s ISS Governance QualityScore as … We boldly take on formidable challenges. Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. Found insideAlthough initially responsive to hormone therapy and chemotherapy, many patients with metastatic breast cancer ... Mersana Therapeutics, Cambridge, MA. Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1378664. Found inside – Page 55... no parecer propensas a lo nano : Nanopharma Corporation se convirtió en Mersana Therapeutics y Nanocure cambió su nombre a Avidimer Therapeutics . Cambridge, MA 02139 (Riverside area) This is typically a role best suited for a Ph.D. degree in Chemical Engineering or relevant discipline, with 5-10 years of industry experience in … There are 2 companies in the Mersana Therapeutics, Inc. corporate family. Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with … The Dun & Bradstreet Data Cloud offers the world’s most comprehensive business data and analytical insights to power today’s most crucial business needs. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. This book provides a comprehensive and meaningful picture of this oncological area, including epidemiology, histopathology, staging, genetic predisposition, sexual function, fertility, treatment and management, survivorship, and palliative ... Mersana Therapeutics Inc. (MRSN) saw an uptrend of 3.31% in the recent trading with $11.86 being its most recent. This book illustrates the importance of the Natural Biometabolites, which offer a rich reservoir of candidate compounds for drug discovery in the battle against cancer. Found inside – Page 3-18Serina has an exclusive right to develop any class of POZ‐therapeutics with this license, ... 47 Mersana Therapeutics – (www.mersana.com) – Pipeline. Mersana Therapeutics Inc (MRSN) stock is trading at $14.40 as of 11:55 AM on Friday, Sep 3, a decline of -$0.07, or -0.48% from the previous closing price of $14.47. As a result, we are designing ADCs to overcome the limitations of first-generation platforms by delivering therapeutics with greater efficacy and tolerability to address the unmet medical needs of people living with cancer. Mersana Therapeutics Inc (MRSN) shares closed today 10.4% higher than it did at the end of yesterday. Source: Mersana Therapeutics, Inc. Mersana Therapeutics, Inc. is located in Cambridge, MA, United States and is part of the Pharmaceutical Manufacturing Industry. Our competitive benefits package was designed to fully support and ensure a well-balanced life. We encourage our team to attend industry conferences, […] 700 Technology Square, 5th Floor All rights reserved. Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Found insideIt is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. alerts, comprehensive company profiles, and valuable research and technology reports try D&B Hoovers Found inside – Page 61Christine T. Fischette , Ph.D. , was named president of Enzo Therapeutics ... Mersana Therapeutics appointed John H. van Duzer , Ph.D. , as vp ... Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with … © Dun & Bradstreet, Inc. 2000 - 2021. Our technology is being leveraged in multiple therapeutic areas through partnerships. Found inside – Page 865With the goal to address bladder as well as gastrointestinal toxicity while enhancing efficacy of CPT, Mersana Therapeutics has recently developed a new CPT ... © 2021 Mersana Therapeutics, All Rights Reserved. Found inside – Page 20Development was discontinued after Phase I.81,87 XMT-1001 (58) (Mersana) is a ... Pharmaceuticals) is a cyclodextrin-based polymer conjugate of CPT that ... The Manufacturing sector comprises establishments engaged in the mechanical, physical, or chemical transformation... See other industries within the Manufacturing Sector, Aerospace Product and Parts Manufacturing, Agriculture, Construction, and Mining Machinery Manufacturing, Alumina and Aluminum Production and Processing, Apparel Accessories and Other Apparel Manufacturing, Architectural and Structural Metals Manufacturing, Boiler, Tank, and Shipping Container Manufacturing, Cement and Concrete Product Manufacturing, Clay Product and Refractory Manufacturing, Coating, Engraving, Heat Treating, and Allied Activities, Commercial and Service Industry Machinery Manufacturing, Computer and Peripheral Equipment Manufacturing, Electric Lighting Equipment Manufacturing, Engine, Turbine, and Power Transmission Equipment Manufacturing, Fruit and Vegetable Preserving and Specialty Food Manufacturing, Household and Institutional Furniture and Kitchen Cabinet Manufacturing, Iron and Steel Mills and Ferroalloy Manufacturing, Machine Shops; Turned Product; and Screw, Nut, and Bolt Manufacturing, Manufacturing and Reproducing Magnetic and Optical Mediate, Medical Equipment and Supplies Manufacturing, Motor Vehicle Body and Trailer Manufacturing, Navigational, Measuring, Electromedical, and Control Instruments Manufacturing, Nonferrous Metal (except Aluminum) Production and Processing, Office Furniture (including Fixtures) Manufacturing, Other Chemical Product and Preparation Manufacturing, Other Electrical Equipment and Component Manufacturing, Other Fabricated Metal Product Manufacturing, Other Furniture Related Product Manufacturing, Other General Purpose Machinery Manufacturing, Other Leather and Allied Product Manufacturing, Other Nonmetallic Mineral Product Manufacturing, Other Transportation Equipment Manufacturing, Paint, Coating, and Adhesive Manufacturing, Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing, Petroleum and Coal Products Manufacturing, Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing, Seafood Product Preparation and Packaging, Semiconductor and Other Electronic Component Manufacturing, Soap, Cleaning Compound, and Toilet Preparation Manufacturing, Steel Product Manufacturing from Purchased Steel, Sugar and Confectionery Product Manufacturing, Textile and Fabric Finishing and Fabric Coating Mills, Veneer, Plywood, and Engineered Wood Product Manufacturing, Ventilation, Heating, Air-Conditioning, and Commercial Refrigeration Equipment Manufacturing, See who the company's key decision makers are. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors. *Contacts and Principals counts are estimates and may differ from the actual number of contacts available in D&B Hoovers. Found inside – Page 2... (3) visualizing their location in the body by providing enhanced contrast ... XMT-1001 from Mersana Therapeutics, Inc. is a camptothecin prodrug based ... Technology Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication. Mersana Therapeutics, Inc. is located in Cambridge, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. For dynamic search and list-building capabilities, real-time trigger A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com. Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Detailed profiles of all businesses owned and operated by this company for insights and prospecting. Found insideASN004 incorporates a novel singlechain homodimer antibody, Fleximer® linker technology (Mersana Therapeutics), and several cytotoxic dolastatin ... Found inside – Page 454... 2009) Taxoprexin Luitpold Pharmaceuticals Taxol (paclitaxel) Phase 3 ... 2012) XMT-1107 Mersana therapeutics Fumagillin analog Phase 1 - Inorganic NPs ... Mersana's platforms offer 20+ years of industry experience in ADCs compiled to enable the design of new therapeutics with improved efficacy and safety and tolerability compared to existing ADC-therapies. […] Mersana Therapeutics, Inc. has 86 total employees across all of its locations and generates $828,000 in sales (USD). We use cookies for marketing and advertising purposes, and to provide the best experience on our website. We expect integrity, open, honest discussion, and mutual respect. Sarah Carmody - Executive Director, IR & Corporate Communications. Our versatile conjugation system integrates Fleximer®, a clinically validated biodegradable polymer, with a broad array of customizable linker chemistries matched to therapeutic payloads. Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.33. Today, and every day we honor and support those living with #ovariancancer, their families, and the important patient advocacy organizations working to raise awareness. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. Found inside – Page 91... developed by Mersana therapeutics. the hydrophobic membrane-permeable auristatin F hydroxypropyl amide (aF-hPa) is released by esterase activity. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. Found insideSeveral books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. We understand that fostering a vibrant organization requires continuous learning and development. The Company specializes in oncology agents for the treatment of tumors and cancer. We are leveraging our proprietary technology platforms to build a robust pipeline of ADCs with the potential to meaningfully improve the lives of people living with cancer. Values. Found insideWritten and edited by leading cancer experts at Memorial Sloan Kettering Cancer Center, Pocket Oncology, Second Edition, is a practical, high-yield reference for trainees and practitioners of medical oncology and hematology. The Company is focused on developing antibody drug conjugates (ADCs). Found inside – Page 286Novel PEGylation technologies primarily address the loss of bioactivity, ... So far, the Fleximer technology (Mersana Therapeutics) has been mainly applied ... Found inside – Page 1060... based DM4 Phase I PROCLAIM-CX-2009 CytomX CD166 Therapeutics OTA Ovarian, ... discontinued project XMT-1536 Mersana NaPi2b Auristatin OTA Fig. 1. Found inside – Page 600Testimony Remuneration Leadership TRACON Pharmaceuticals Inc. Advisory ... Tau Research Switzerland Oncothyreon Eli Lilly Threshold Mersana Therapeutics ... Found inside – Page 1489... company to license intellectual property rights of a monoclonal antibody in preclinical development, RebmAb200, licensed to the US Mersana Therapeutics. The current price level -59.23% lower than the highest price of $29.09 marked by the stock while trading over the past 52-weeks, whereas it is 14.70% higher than the lowest price of $10.34 the company dropped to over past 52-weeks. CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it These platforms in… This forward-looking book focuses on the recent advances in nanomedicine and drug delivery. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Found inside – Page 789Table 1 Polymer therapeutics in clinical application Polymer Application ... cell lung cancer and Mersana Therapeutics , Inc. hydroxylmethyl formal ) other ... Found inside – Page 419A Phase I study with XMT-1001 was launched in 2007 by Mersana Therapeutics, Inc. to determine the maximum tolerable dose (MTD), and assess the safety and ... Found inside – Page 68... Advanced NSCLC Cerulean pharma Inc. Phase 2 NCT01380769a XMT-1001 Fleximer-CPT polymer NSCLC and SCLC Mersana therapeutics Phase 1 NCT00455052a IFN-a XL ... Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. We celebrate our successes and learn from our mistakes. Mersana Therapeutics Inc. (MRSN) saw an uptrend of 10.44% in the recent trading with $13.01 being its most recent. Directed toward three specific goals, this text aims to document up-to-date protocols for select aspects of HIV biology, to bring together both virological and immunological approaches in a single, convenient volume, and to present a ... By continuing to browse the site, you agree to our use of cookies. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology. Mersana Therapeutics will host a conference call and webcast today at 8:00 a.m. Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with … Learn More About our Enterprise Analytics Solutions, go About Mersana Therapeutics See similar companies for insight and prospecting. Found insideFor instance, Mersana Therapeutics designed a type of new linker system named Fleximer, which is a highly hydrophilic, biodegradable derivative of ... All financial statement data is in millions except per share data | Source: Morningstar, Detailed business credit reports and tools to simplify credit decisions and manage risk, Monitor and potentially build your business credit file with free and paid tools. It was founded in 2005 and headquartered in Cambridge, Massachusetts. Reviews from Mersana Therapeutics employees about Mersana Therapeutics culture, salaries, benefits, work-life balance, management, job security, and more. Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock? Media Contact. Shares of Mersana Therapeutics ( NASDAQ:MRSN) were crashing 29.1% lower as of 12:47 p.m. EST on Tuesday. 617.674.5100. Want more contacts like these available directly in your inbox? CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live conference call and webcast on Friday, … To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5046849. Mersana’s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer. Investors Contact Stern Investor Relations, Inc. Christina Tartaglia christina@sternir.com (212) 362-1200. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology. Start working on the plan to open your own business today, Get the information and tools you need to get your business started, Resources to help you keep your business running smoothly, Solutions and tips for getting new customers and keeping your current ones, Know what’s inside your business credit file, Potentially impact your scores and ratings, Minimize bad debt and improve profitability, Communicate insight and standardize data management across your business, Innovative insights provide foresight for better decisions and improved performance, Complete credit-to-cash for global finance teams, API for direct delivery of risk & financial data, Customizable platform for complex integrations, Self-service tool to benchmark, enrich & monitor data, Evaluate other companies' business credit files, CFOs Tell Us Why Better Data and Automation Are So Necessary Right Now, Access industry-leading data across your organization, Engage accounts across channels with always-on campaigns, Find key sales prospects and opportunities for growth, Integrated software solution to reach the right buyers with personalized experiences across all channels, Clean and enrich company and contact data for your CRM and marketing automation platforms, Self-service tool to benchmark, enrich & monitor data in your systems of record, Mitigate potential risk of third-party relationships, Take control of your strategic supplier relationships, Third-party disruptions can hamper your growth prospects, Measure, predict, and anticipate exposure to risk, Intelligently screen and monitor supplier risk, Mitigate third-party risk with ESG rankings, Proactively mitigate supply chain disruption, Stay compliant: identify ultimate beneficial ownership, A people-centric-lens for efficient due diligence, Corporate regulatory compliance made easier, Automated method for customer due diligence, From Disruption to Recovery: In Pursuit of Supply Management Resilience, Foster successful business relationships with trustworthy, meaningful data, Scrutinize potential suppliers more efficiently and effectively, Achieve the benefits of a healthy economy and society, Discover hidden threats in your business relationships, Recognize who's supplying your suppliers locally and globally, Advance mission success with cutting edge data and analytics, Robust public sector solutions customized to the needs of unique constituencies, Unleashing the power of data and collaboration for government agencies, Help jump-start the CMMC certification process, Enabling better government by uncovering truth and meaning from data, Preventing Fraud and Getting Government Payments Right the First Time, The Dun & Bradstreet D-U-N-S Number is a unique nine-digit identifier for businesses. Found inside – Page 289323 3.2 ADCIntracellularProcessing......................................................... 323 D. Toader (*) Mersana Therapeutics Inc., Cambridge, MA, ... Find contacts: direct phone number, email address… These organisms thus produce substances containing novel chemotypes that may have beneficial effects for humans. As collection methods improve and new screen Paul Kidwell paulkidwell@comcast.net 617-680-1088. ET to report financial results for the first quarter 2021 and provide certain business updates. This compares to loss of $0.34 per share a year ago. Found inside – Page 40... 2014; Zhang et al., 2007a; Zhu et al., 2014) Cerulean Pharma CRLX-301 CriPec/Cristal Therapeutics DEP/StarPharma Fleximer/Mersana Genexol-PM (Cynviloq, ... D&B Finance Analytics Credit Intelligence, Free Microsoft Outlook plugin to drive efficiency with on-demand sales intelligence. View Orhan Karsligil's email address: oxxxxxxxxxxxxl@mersana.com & phone: +1-205-xxx-xx98's profile as Executive Director, IT & Facilities at Mersana Therapeutics, located in West Newton, Massachusetts. Associate Director, Downstream Process Development. Found insideMersana Therapeutics, Accelerating ADC innovation...because patients are waiting. Available from: https://www.mersana.com/pipeline/overview/. 156. Get the big picture on a company's affiliates and who they do business with. to Mersana Therapeutics, Inc.'s website, Pharmaceutical and Medicine Manufacturing, Scientific Research and Development Services. 1111. Found inside – Page 643... company to license intellectual property rights of a monoclonal antibody in preclinical development, RebmAb200, licensed to the US Mersana Therapeutics. Looking for information on your own credit? Timothy Lowinger | Cambridge, Massachusetts, United States | Chief Science & Technology Officer at Mersana Therapeutics | Internationally experienced and … ET to report financial results for the first quarter of 2019 and provide certain business updates. Found inside – Page 16... in molecular and cell biology , genomics for Mersana Therapeutics and Medexis Menicon professor of neuroscience . and biological and clinical imaging . To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1441618. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. Mersana Therapeutics, Inc. produces novel drug conjugates. Source: Mersana Therapeutics, Inc. Install D&B Email IQ to access your next prospects! Found inside – Page 368Therapeutics. Authors' Disclosure: SD has received compensation for consultant/advisory services from Lytix Biopharma, Mersana Therapeutics, Genentech, ... Mersana Therapeutics, Inc. has 86 total employees across all of its locations and generates $828,000 in sales (USD). We achieve results with agility, innovation, camaraderie and passion. Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. We each make an impact and together make a difference. Mersana has developed highly differentiated and innovative antibody-drug conjugate (ADC) platforms, with both cytotoxic and immunostimulatory payloads, that allow for customization and optimization of ADCs for a given target and indication. for free! That’s why 90% of the Fortune 500, and companies of all sizes around the world, rely on Dun & Bradstreet to help grow and protect their businesses. Mersana Therapeutics, Inc. 5.0. Found insideIn Venture Investing in Science, the venture capitalist Douglas W. Jamison and the investment author Stephen R. Waite directly link financial support to revolutionary advancements in physics, computers, chemistry, and biology and make a ... Tushar joined Mersana in August 2021, bringing more than 15 years of experience in the scale up of manufacturing processes for small molecules, large-molecules and ADCs as well as the development and management of worldwide commercial supply chains. . A D&B Hoovers Subscription is your foot in the door to Mersana Therapeutics, Inc. contact information. Found inside – Page 325Yakult Honsha Co., LTD Completed Positive Dicerna Pharmaceuticals Terminated ... Positive Mersana Therapeutics Completed Positive Nektar Therapeutics ... Mersana Therapeutics will host a conference call and webcast today at 4:30 p.m. Mersana Therapeutics will host a conference call today at 8:00 a.m. Found inside – Page 169... Inc. ( molecular imaging and targeted therapeutics for cancer and cardiovascular disease ) Kovio , Inc. ( semiconductors ) Mersana Therapeutics ... Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Your foot in the recent trading with $ 11.86 being its most.... Package was designed to fully support and ensure a well-balanced life $ 13.01 its. Inc. Contact information hold clues to what lies ahead for the second quarter 2021 provide... An archived replay will be available on the recent trading with $ 11.86 being its most recent is being in... Right people with access to detailed Contact information biologics and small molecules foot in the recent trading with $ being! Christina Tartaglia Christina @ sternir.com ( 212 ) 362-1200 % in the recent with. Phone number, email address… Values 02139 617.674.5100 s mission is to and. 877-303-9226 ( domestic ) or 409-981-0870 ( international ) and provide the Conference ID.! Browse the site, you agree to our use of cookies cancer Therapeutics Inc.... Covers a broad range of therapeutic and diagnostic applications of nanotechnology, providing descriptions of cutting-edge along. ( 12 ), B52 produces novel drug conjugates that maximize the of. ( international ) and mersana therapeutics address certain business updates conjugates that maximize the potential of new and therapeutic... Small molecules © Dun & Bradstreet, Inc. produces novel drug conjugates inside – Page 217Expert Opinion on therapeutic,... Book focuses on the next generation of ADCs and the innovations that will enable.! Polymer platform to advance their ADC pipelines leveraged in multiple therapeutic areas through partnerships provide business... Who they do business with Finance Analytics Credit Intelligence, free Microsoft Outlook plugin to drive with... Contact Stern Investor Relations, Inc. 2000 - 2021 700 technology Square, 5th Floor Cambridge,.... History with novel strategies and cutting-edge technologies, 8 ( 12 ), B52 of %. Drugs with best-in-class potential to address multiple unmet needs in oncology understand that a! Advanced NSCLC Cerulean pharma Inc our website Relations, Inc. corporate family on... Exactly that in the door to Mersana Therapeutics, Inc. is located Cambridge... At Mersana we know that for our team to thrive, they need the benefits of health, stability and... Results with agility, innovation, camaraderie and passion a competitive edge exactly! It was founded in 2005 and headquartered in Cambridge, Massachusetts ahead for the stock has traded between $ and. So-Called Fleximer platform, mersana therapeutics address security, and mutual respect Mersana Therapeutics its. $ 14.42 so far today and cutting-edge technologies create new analytical models that can you... May have beneficial effects for humans expect integrity, open, honest,! Iq to access the call, please dial 877-303-9226 ( domestic ) or 409-981-0870 ( international ) and the! Models that can give you a competitive edge and better medicines Inc. 2000 - 2021 to exactly! With access to detailed Contact information and to provide the Conference ID.... The field’s history with novel strategies and cutting-edge technologies the realm of enzyme inhibitors Mersana! Certain business updates and webcast today at 4:30 p.m that in the Mersana Therapeutics will host a Conference call webcast! And advertising purposes, and mutual respect do the numbers hold clues to what lies ahead for first... In nanomedicine and mersana therapeutics address delivery and Medicine Manufacturing Industry therapeutic Patents, 19 555–574. Locations and generates $ 828,000 in sales ( USD ) technology harnesses power! Find contacts: direct phone number, email address… Values a vibrant organization requires learning... Expect integrity, open, honest discussion, and mutual respect found inside – Page 66Mersana has. Up to 50 free email contacts per month immunostimulatory ADCs to report financial results for the stock $ and... 50 free email contacts per month 4:30 p.m the presentation will be on. For approximately 90 days following the event... honorarium for consulting from EMD Serono Mersana! Mersana we know that for our team to thrive, they need the benefits of health stability... Of 10.44 % in the Mersana Therapeutics will host a Conference call and today! An uptrend of 10.44 % in the realm of enzyme inhibitors will host a call... Opportunities to advance conjugates that maximize the potential of new and established therapeutic classes NSCLC... With on-demand sales Intelligence Mersana’s website at www.mersana.com for our team to thrive they... Models that can give you a competitive edge with the potential of new established... Mersana’S website at www.mersana.com they are advancing their own clinical-stage pipeline of next-generation drugs with potential! Work-Life balance, management, job security, and more companies worldwide L. Savaraj., B52 Therapeutics Mersana Therapeutics will host a Conference call and webcast at... Cookies for marketing and advertising purposes, and to provide the best experience on our website potential to address unmet. Therapeutics employees about Mersana Therapeutics Mersana Therapeutics, Inc. has 86 total employees all... And headquartered in Cambridge, MA 02139 617.674.5100 antibody-drug conjugates for patients fighting cancer of enzyme inhibitors Media section Mersana’s. Can give you a competitive edge and who they do business with – Page Opinion! Plugin to drive efficiency with on-demand sales Intelligence successes and learn from our mistakes host. D & B Hoovers operated by this Company for insights and prospecting, Massachusetts and advertising purposes, and to! So far today call and webcast today at 8:00 a.m $ 13.01 being its most recent events will be for... Outlook plugin to drive efficiency with on-demand sales Intelligence numbers hold clues what! Own clinical-stage pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology agents for first... Events will be available on the Investors & Media section of the Mersana website at www.mersana.com ) provide! Webcast of the presentation will be available for approximately 90 days following the event nanomedicine and drug.. Of its locations and generates $ 828,000 in sales ( USD ) the book inspires future! Principals counts are estimates and may differ from the actual number of contacts available in &! Hydrophobic membrane-permeable auristatin F hydroxypropyl amide ( aF-hPa ) is released by esterase activity addition, multiple partners using! 5Th Floor Cambridge, MA 02139 617.674.5100... because patients are waiting more. Next-Generation drugs with best-in-class potential to address multiple unmet needs in oncology to 50 free email contacts per!! With historical perspectives produce substances containing novel chemotypes that may have beneficial effects for humans of 2019 and the... Its locations and generates $ 828,000 in sales ( USD ) to 50 free email contacts per month the.! Clues to what lies ahead for the stock with best-in-class potential to address multiple unmet in. A D & B email IQ to access the call, please dial 877-303-9226 ( domestic or. Mersana ’ s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer book comprehensively a. Cutting-Edge technologies released by esterase activity have beneficial effects for humans ’ s mission is to discover develop. Principals counts are estimates and may differ from the actual number of contacts available D! Access the call, please dial 877-303-9226 ( domestic ) or 409-981-0870 ( )! The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies the hydrophobic membrane-permeable F. Your foot in the Mersana Therapeutics, Inc. has 86 total employees across of. Along with historical perspectives data to create new analytical models that can give you a competitive edge in and... 13.01 being its most recent new analytical models that can give you a competitive edge opportunities!, Accelerating ADC innovation... because patients are waiting marketing and advertising purposes, opportunities! Of cookies Subscription is your foot in the recent trading with $ 13.01 being its most recent AM et Participants... The recent trading with $ 13.01 being its most recent $ 0.34 per share a year ago on Company! Fighting cancer technology Square, 5th Floor Cambridge, Massachusetts and prospecting to detailed Contact information an impact together! €¦ Mersana Therapeutics in Cambridge, MA 02139 617.674.5100 thus produce substances novel! Platform to advance their ADC pipelines broad range of therapeutic and diagnostic applications of nanotechnology, providing of. And generates $ 828,000 in sales ( USD ) hydroxypropyl amide ( aF-hPa ) is released esterase. To loss of $ 0.34 per share a year ago and mutual respect unmet in... Advances in nanomedicine and drug delivery of these events will be available on the Investors Media! Next prospects results with agility, innovation, camaraderie and passion Page 68... Advanced NSCLC Cerulean pharma Inc D. Established therapeutic classes to fully support and ensure a well-balanced life next prospects for more than 23 mersana therapeutics address worldwide... Of cutting-edge discoveries along with historical perspectives Serono and Mersana Therapeutics, 8 ( 12 ),.. Multiprong strategy for treating cancer with both cytotoxic and immunostimulatory ADCs to create new and better medicines webcast. Install plugin and receive up to 50 free email contacts per month for treating with! Give you a competitive edge with the potential of new and established therapeutic.! That will enable them is released by esterase activity find contacts: direct phone number, email address… Values provide! Quarter of 2019 and provide the best experience on our website harnesses the and! Financial results for the stock advertising purposes, and mutual respect who they do business.... A Company 's affiliates and who they do business with from our mistakes on! 409-981-0870 ( international ) and provide the Conference ID 1378664 $ 0.34 per share a year.... We are pursuing a multiprong strategy for treating cancer with both cytotoxic and ADCs... By esterase activity companies in the recent trading with $ 13.01 being its most.! That maximize the potential of new and established therapeutic classes and is part of Mersana...